Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Recent & Breaking News (OTCQX:CSLLY)

Biotech Leader CSL Again Named Among America's Best Employers by Forbes

PR Newswire February 21, 2023

CSL Announces Next CEO & Managing Director

PR Newswire December 12, 2022

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

PR Newswire December 12, 2022

CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment

PR Newswire December 10, 2022

U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

PR Newswire November 22, 2022

Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022

PR Newswire November 2, 2022

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

PR Newswire November 1, 2022

CSL Plasma Expands in California with New Donation Centers to Collect Life-Saving Plasma

PR Newswire October 11, 2022

CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine

PR Newswire October 6, 2022

CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

PR Newswire October 5, 2022

New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates

PR Newswire September 26, 2022

New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems

PR Newswire September 26, 2022

CSL presents new research and development center in Marburg, Germany

PR Newswire September 13, 2022

CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI

PR Newswire September 13, 2022

CSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors

PR Newswire September 8, 2022

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

GlobeNewswire August 22, 2022

CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

PR Newswire August 17, 2022

CSL announces carbon emissions reduction targets

PR Newswire August 16, 2022

CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY

PR Newswire August 10, 2022

CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology

PR Newswire August 4, 2022